Our Blog - ELIAS Animal Health: Insights on Cancer Immunotherapy

ELIAS Animal Health Announces Apheresis Partnership with CTAC, Expanding Access to Cancer Immunotherapy in Southeast U.S.

LENEXA, Kan., Feb. 13, 2025 -- In alignment with our commitment to expand access to innovative veterinary cancer care across [...]

February 13th, 2025|

LENEXA, Kan., July 31, 2024 /PRNewswire/ -- ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer [...]

July 31st, 2024|

OLATHE, Kan., April 30, 2024 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, is expanding its [...]

April 30th, 2024|

Experienced executive will lead launch of the first USDA-approved immunotherapy for the treatment of bone cancer in dogs OLATHE, Kan., [...]

April 10th, 2024|

ELIAS Animal Health CEO, Tammie Wahaus, returns to the Dog Cancer Answers podcast to talk about ECI® as an alternative [...]

April 1st, 2024|

First-in-class adoptive cell therapy for treatment of osteosarcoma, a deadly form of bone cancer in dogs OLATHE, Kan., Jan. 17, [...]

January 17th, 2024|

After successfully concluding a clinical trial for canine osteosarcoma, ELIAS Animal Health is focused on continuing to push forward in [...]

November 2nd, 2023|